Mayo Clinic Health Manager
Get free personalized health guidance for you and your family.
Get Started
close window
Housecall Archives
About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
close window
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Risk factors
By Mayo Clinic staffITP is a fairly common blood disorder and can strike anyone at almost any age, but these factors increase your risk:
- Your sex. Girls and younger women are about twice as likely to develop ITP as men are, but the gap narrows as people age.
- Age. Once considered a young person's disease, ITP is actually far more common in people older than 60 than it is in younger adults.
- Recent viral infection. Many children with ITP develop the disorder after a viral illness, such as mumps, measles or a respiratory infection. In most children, ITP clears on its own within two to eight weeks.
References
- ITP: Idiopathic thrombocytopenic purpura. American Academy of Family Physicians. http://familydoctor.org/online/famdocen/home/common/blood/113.html. Accessed July 31, 2008.
- What is idiopathic thrombocytopenic purpura? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/dci/Diseases/Itp/ITP_WhatIs.html. Accessed July 31, 2008.
- George JN. Treatment and prognosis of idiopathic thrombocytopenic purpura in adults. http://www.uptodate.com/home/index.html. Accessed July 31, 2008.
- Rodeghiero F. Idiopathic thrombocytopenic purpura: An old disease revisited in the era of evidence-based medicine. Haematologica. 2003; 88(10):1081-1087.
- Stasi R, et al. Management of immune thrombocytopenic purpura in adults. Mayo Clinic Proceedings. 2004;79(4):504-522. http://www.mayoclinicproceedings.com/pdf%2F7904%2F7904r.pdf.
- Bussel JB, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine. 2007;357(22):2237-2247. http://content.nejm.org/cgi/content/abstract/357/22/2237. Accessed July 31, 2008.
- Rodeghiero F. First-line therapies for immune thrombocytopenic purpura: Re-evaluating the need to treat. European Journal of Haematology. 2008; 80(69)(suppl):19-26.
- Newland A. Emerging strategies to treat chronic immune thrombocytopenic purpura. European Journal of Haematology. 2008;80(69)(suppl):27-33.
